Whole-Body Diffusion-weighted Imaging in Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.

Abstract

Whole-body imaging, in particular molecular imaging with fluorine 18 ((18)F)-fluorodeoxyglucose (FDG) positron emission tomography (PET), is essential to management of lymphoma. The assessment of disease extent provided by use of whole-body imaging is mandatory for planning appropriate treatment and determining patient prognosis. Assessment of treatment response allows clinicians to tailor the treatment strategy during therapy if necessary and to document complete remission at the end of treatment. Because of rapid technical developments, such as echo-planar sequences, parallel imaging, multichannel phased-array surface coils, respiratory gating, and moving examination tables, whole-body diffusion-weighted (DW) magnetic resonance (MR) imaging that reflects cell density is now feasible in routine clinical practice. Whole-body DW MR imaging allows anatomic assessment as well as functional and quantitative evaluation of tumor sites by calculation of the apparent diffusion coefficient (ADC). Because of their high cellularity and high nucleus-to-cytoplasm ratio, lymphomatous lesions have low ADC values and appear hypointense on ADC maps. As a result, whole-body DW MR imaging with ADC mapping has become a promising tool for lymphoma staging and treatment response assessment. The authors review their 4 years of experience with 1.5-T and 3-T whole-body DW MR imaging used with (18)F-FDG PET/computed tomography at baseline, interim, and end of treatment in patients with Hodgkin lymphoma and diffuse large B-cell lymphoma and discuss the spectrum of imaging findings and potential pitfalls, limitations, and challenges associated with whole-body DW MR imaging in these patients.

• Authors: Sarah Toledano-Massiah, Alain Luciani, Emmanuel Itti, Pierre Zerbib, Alexandre Vignaud, Karim Belhadj, Laurence Baranes, Corinne Haioun, Chieh Lin, Alain Rahmouni
• Journal: Radiographics : a review publication of the Radiological Society of North America, Inc (Radiographics) 2015 May-Jun Vol. 35 Issue 3 Pg. 747-64 ISSN: 1527-1323 [Electronic] United States
• PMID: 25815803 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: (©)RSNA, 2015.

Chemical References

• Radiopharmaceuticals
• Fluorodeoxyglucose F18

Topics

• Diffusion Magnetic Resonance Imaging
• Fluorodeoxyglucose F18
• Hodgkin Disease (pathology, therapy)
• Humans
• Lymphoma, Large B-Cell, Diffuse (pathology, therapy)
• Multimodal Imaging
• Neoplasm Staging
• Positron-Emission Tomography
• Radiopharmaceuticals
• Tomography, X-Ray Computed
• Whole Body Imaging